Thursday July 18, 2019

People Who Take Cholesterol-Lowering Statins are at Higher Risk of Developing Type 2 Diabetes

More than a quarter of middle-aged adults use a cholesterol-lowering drug, according to estimates

0
//
Research, Cholesterol, Diabetes
Statins are a class of drugs that can lower cholesterol and blood pressure, reducing the risk of heart attack and stroke. Pixabay

People who take cholesterol-lowering statins may be at twice the risk of developing type 2 diabetes, says a new study.

Statins are a class of drugs that can lower cholesterol and blood pressure, reducing the risk of heart attack and stroke. More than a quarter of middle-aged adults use a cholesterol-lowering drug, according to estimates.

The study, published in the Diabetes Metabolism Research and Reviews journal, found that statin users had more than double the risk of diagnosis compared to those who didn’t take the drugs. Those who took the cholesterol-lowering drugs for more than two years had more than three times the risk of diabetes.

“The fact that increased duration of statin use was associated with an increased risk of diabetes – something we call a dose-dependent relationship – makes us think that this is likely a causal relationship,” said the study’s lead author Victoria Zigmont, a graduate student at the Ohio State University.

Research, Cholesterol, Diabetes
People who take cholesterol-lowering statins may be at twice the risk of developing type 2 diabetes. Pixabay

“Statins are very effective in preventing heart attacks and strokes. I would never recommend that people stop taking the statin they’ve been prescribed based on this study, but it should open up further discussions about diabetes prevention,” Zigmont added.

For the study, the researchers included over 4,000 men and women who did not have diabetes, were candidates for statins based on heart disease risk and had not yet taken the drugs at the start of the study. About 16 per cent of the group – 755 patients – were eventually prescribed statins during the study period.

Researchers also found that statin users were 6.5 percent more likely to have a troublingly high HbA1c value – a routine blood test for diabetes that estimates average blood sugar over several months.

Also Read- Research: Policies Need to be Context-Specific to Improve Women’s Lives in Rural India

“Although statins have clear benefits in appropriate patients, scientists and clinicians should further explore the impact of statins on human metabolism, in particular the interaction between lipid and carbohydrate metabolism,” said co-author Steven Clinton, a Professor at the varsity. (IANS)

Next Story

OPPO to Establish New Research and Development Centre in China to Boost its R&D Capabilities

The smartphone player will spend 10 billion Renminbi (around $1.46 billion) on R&D this year

0
The new facilities, along with the company's existing R&D centres, will form a robust research engine that powers its innovation for the emerging era of intelligent connectivity. Pixabay

Chinese handset maker OPPO on Friday announced it will establish a new research and development centre in China’s Chang’an Town, Dongguan, Guangdong Province as it aims to boost its R&D capabilities.

The new facilities, along with the company’s existing R&D centres, will form a robust research engine that powers its innovation for the emerging era of intelligent connectivity.

The smartphone player will spend 10 billion Renminbi (around $1.46 billion) on R&D this year.

“We are very pleased to officially break ground on OPPO’s new Chang’an R&D centre. It will play a strategic role in OPPO’s R&D endeavours, further enhancing the core technological capabilities of the company and accelerating the implementation of our R&D strategy and objectives,” Eric Zhu, Vice President, OPPO, said in a statement.

OPPO, Research, Development
Chinese handset maker OPPO on Friday announced it will establish a new research and development centre in China’s Chang’an Town. Pixabay

“The project will be built to the highest industrial standards and we will spare no effort in making the new R&D centre a masterpiece initiative in the Guangzhou-Shenzhen Science and Technology Innovation Corridor, helping to bolster the development of the Guangdong-Hong Kong-Macao Greater Bay Area.”

According to the handset maker, OPPO’s Chang’an R&D centre is one of Dongguan’s major initiatives to drive the development of the Guangdong-Hong Kong-Macao Greater Bay Area, and is expected to house 5,000 R&D personnel upon completion.

Also Read- India: Gau Seva Aayog to Provide the Person Transporting Cows with Certificate

As a global R&D engine for the company, the R&D centre will be responsible for the R&D, design and testing of a range of smart devices, including smartphones and IoT products.(IANS)